International Study of Ezetimibe/Simvastatin Cholesterol Lowering and Major Vascular Events in Chronic Kidney Disease.

Trial Profile

International Study of Ezetimibe/Simvastatin Cholesterol Lowering and Major Vascular Events in Chronic Kidney Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
  • Indications Cardiovascular disorders; Stroke
  • Focus Therapeutic Use
  • Acronyms SHARP
  • Sponsors Merck/Schering-Plough Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 12 Mar 2014 United Kingdom Clinical Research Network reports accrual to date as 100%
    • 31 May 2012 Planned number of patients changed from 9000 to 9438 and additional locations added as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top